Cell Communication and Signaling,
Journal Year:
2024,
Volume and Issue:
22(1)
Published: Feb. 8, 2024
Abstract
Background
Our
previous
studies
demonstrated
that
1-Pyrroline-5-carboxylate
(P5C)
released
by
prostate
cancer
cells
inhibits
T
cell
proliferation
and
function
increasing
SHP1
expression.
We
designed
this
study
to
further
explore
the
influence
of
P5C
on
metabolism,
produced
an
antibody
for
targeting
restore
functions
cells.
Method
co-immunoprecipated
from
analyzed
proteins
were
bound
it
using
liquid
chromatography
mass
spectrometry
(LC/MS-MS).
The
metabolism
was
also
detected
LC/MS-MS.
Seahorse
XF96
analyzer
used
identify
effect
glycolysis.
subsequently
monoclonal
technique
verified
its
effectiveness
in
vitro
vivo.
Result
PKM2
LDHB
bind
cells,
could
increase
levels
p-PKM2
while
having
no
LDHB.
found
influences
energy
carbohydrate
metabolism.
activity
decreases
content
intracellular
lactic
acid
LDH.
Using
seahorse
analyzer,
we
confirmed
remarkably
glycolysis
oppose
process
Meanwhile,
growth
tumors
animal
model.
Conclusion
revealed
SHP1/PKM2/LDHB
complexes.
Moreover,
is
important
inhibit
tumors.
Science Immunology,
Journal Year:
2023,
Volume and Issue:
8(82)
Published: April 14, 2023
Chimeric
antigen
receptor
(CAR)
T
cells
have
achieved
true
clinical
success
in
treating
hematological
malignancy
patients,
laying
the
foundation
of
CAR
as
a
new
pillar
cancer
therapy.
Although
these
promising
effects
generated
strong
interest
expanding
treatment
to
solid
tumors,
reproducible
demonstration
efficacy
setting
tumors
has
remained
challenging
date.
Here,
we
review
how
metabolic
stress
and
signaling
tumor
microenvironment,
including
intrinsic
determinants
response
cell
therapy
extrinsic
obstacles,
restrict
treatment.
In
addition,
discuss
use
novel
approaches
target
rewire
programming
for
manufacturing.
Last,
summarize
strategies
that
aim
improve
adaptability
enhance
their
potency
mounting
antitumor
responses
survival
within
microenvironment.
Signal Transduction and Targeted Therapy,
Journal Year:
2024,
Volume and Issue:
9(1)
Published: Oct. 18, 2024
Immunotherapy
has
made
significant
strides
in
cancer
treatment,
particularly
through
immune
checkpoint
blockade
(ICB),
which
shown
notable
clinical
benefits
across
various
tumor
types.
Despite
the
transformative
impact
of
ICB
treatment
therapy,
only
a
minority
patients
exhibit
positive
response
to
it.
In
with
solid
tumors,
those
who
respond
well
typically
demonstrate
an
active
profile
referred
as
"hot"
(immune-inflamed)
phenotype.
On
other
hand,
non-responsive
may
distinct
"cold"
(immune-desert)
phenotype,
differing
from
features
tumors.
Additionally,
there
is
more
nuanced
"excluded"
positioned
between
and
categories,
known
type.
Effective
differentiation
understanding
intrinsic
factors,
characteristics,
TME,
external
factors
are
critical
for
predicting
results.
It
widely
accepted
that
therapy
exerts
profound
effect
on
limited
efficacy
against
or
"altered"
necessitating
combinations
therapeutic
modalities
enhance
cell
infiltration
into
tissue
convert
tumors
ones.
Therefore,
aligning
traits
this
review
systematically
delineates
respective
influencing
extensively
discusses
varied
approaches
drug
targets
based
assess
efficacy.
Frontiers in Oncology,
Journal Year:
2024,
Volume and Issue:
14
Published: March 20, 2024
Immune
checkpoint
molecules
are
a
group
of
expressed
on
the
surface
immune
cells
that
primarily
regulate
their
homeostasis.
Chimeric
antigen
receptor
(CAR)
T
cell
therapy
is
an
immunotherapeutic
technology
realizes
tumor-targeted
killing
by
constructing
synthetic
expressing
specific
antigens
through
biotechnology.
Currently,
CAR-T
has
achieved
good
efficacy
in
non-solid
tumors,
but
its
treatment
solid
tumors
not
yielded
desired
results.
inhibitors
(ICIs)
combined
with
novel
combination
high
expectations
to
defeat
tumors.
This
review
addresses
challenges
and
this
Molecular Cancer,
Journal Year:
2024,
Volume and Issue:
23(1)
Published: Aug. 20, 2024
Gastric
cancer
(GC)
is
one
of
the
deadliest
malignant
tumors
with
unknown
pathogenesis.
Due
to
its
treatment
resistance,
high
recurrence
rate,
and
lack
reliable
early
detection
techniques,
a
majority
patients
have
poor
prognosis.
Therefore,
identifying
new
tumor
biomarkers
therapeutic
targets
essential.
This
review
aims
provide
fresh
insights
into
enhancing
prognosis
GC
by
summarizing
processes
through
which
microRNAs
(miRNAs)
regulate
microenvironment
(TME)
highlighting
their
critical
role
in
TME.
A
comprehensive
literature
was
conducted
focusing
on
interactions
among
cells,
extracellular
matrix,
blood
vessels,
cancer-associated
fibroblasts,
immune
cells
within
The
noncoding
RNAs,
known
as
miRNAs,
modulating
TME
various
signaling
pathways,
cytokines,
growth
factors,
exosomes
specifically
examined.
Tumor
formation,
metastasis,
therapy
are
significantly
influenced
miRNAs
progression
these
multiple
exosomes.
Dysregulation
affects
cellular
such
cell
proliferation,
differentiation,
angiogenesis,
contributing
pathogenesis
GC.
play
crucial
regulation
TME,
influencing
patient
By
understanding
mechanisms
control
potential
can
be
identified
improve
Cancer Research,
Journal Year:
2023,
Volume and Issue:
84(2), P. 258 - 275
Published: Nov. 6, 2023
Abstract
Although
immunotherapy
can
prolong
survival
in
some
patients
with
head
and
neck
squamous
cell
carcinoma
(HNSCC),
the
response
rate
remains
low.
Clarification
of
critical
mechanisms
regulating
CD8+
T-cell
infiltration
dysfunction
tumor
microenvironment
could
help
maximize
benefit
for
treating
HNSCC.
Here,
we
performed
spatial
transcriptomic
analysis
HNSCC
specimens
differing
immune
single-cell
RNA
sequencing
five
pairs
adjacent
tissues,
revealing
specific
cancer-associated
fibroblast
(CAF)
subsets
related
to
restriction
dysfunction.
These
CAFs
exhibited
high
expression
CXCLs
(CXCL9,
CXCL10,
CXCL12)
MHC-I
enrichment
galectin-9
(Gal9).
The
proportion
MHC-IhiGal9+
was
inversely
correlated
abundance
a
TCF1+GZMK+
subset
T
cells.
Gal9
on
induced
decreased
tumor-infiltrating
TCF1+CD8+
Collectively,
identification
advances
understanding
precise
role
cancer
evasion
paves
way
more
effective
Significance:
Spatial
identifies
IFN-induced
that
form
trap
cells,
providing
insights
into
complex
networks
regulate
function.
Molecular Cancer,
Journal Year:
2023,
Volume and Issue:
22(1)
Published: Aug. 30, 2023
Recent
advances
in
neoantigen
research
have
accelerated
the
development
of
tumor
immunotherapies,
including
adoptive
cell
therapies
(ACTs),
cancer
vaccines
and
antibody-based
therapies,
particularly
for
solid
tumors.
With
next-generation
sequencing
bioinformatics
technology,
rapid
identification
prediction
tumor-specific
antigens
(TSAs)
has
become
possible.
Compared
with
tumor-associated
(TAAs),
highly
immunogenic
TSAs
provide
new
targets
personalized
immunotherapy
can
be
used
as
prospective
indicators
predicting
patient
survival,
prognosis,
immune
checkpoint
blockade
response.
Here,
characterization
neoantigens
clinical
application
neoantigen-based
TCR-T
strategies
are
summarized,
current
status,
inherent
challenges,
translational
potential
these
discussed.
Cell Death and Disease,
Journal Year:
2023,
Volume and Issue:
14(12)
Published: Dec. 16, 2023
Abstract
Pyroptosis
is
a
novel
regulated
cell
death
(RCD)
mode
associated
with
inflammation
and
innate
immunity.
Gasdermin
E
(GSDME),
crucial
component
of
the
gasdermin
(GSDM)
family
proteins,
has
ability
to
convert
caspase-3-mediated
apoptosis
pyroptosis
cancer
cells
activate
anti-tumor
Accumulating
evidence
indicates
that
GSDME
methylation
holds
tremendous
potential
as
biomarker
for
early
detection,
diagnosis,
prognosis,
treatment
tumors.
In
fact,
GSDME-mediated
performs
dual
role
in
therapy.
On
one
side,
pyroptotic
tumors
caused
by
contributes
inflammatory
cytokines
release,
which
transform
tumor
immune
microenvironment
(TIME)
from
‘cold’
‘hot’
state
significantly
improve
immunotherapy.
However,
due
expressed
nearly
all
body
tissues
cells,
it
can
exacerbate
chemotherapy
toxicity
partially
block
response.
How
achieve
balance
between
two
sides
research
topic.
Meanwhile,
functions
anti-programmed
protein
1
(PD-1)
therapy,
antibody-drug
conjugates
(ADCs)
chimeric
antigen
receptor
T
(CAR-T
cells)
therapy
have
not
yet
been
fully
understood,
how
clinical
outcomes
persists
obscure.
this
review,
we
systematically
summarize
latest
regarding
molecular
mechanisms
discuss
immunity
its
applications
treatment.
